Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Ironwood and AstraZeneca Begin Phase III China Trial for Linaclotide

publication date: Sep 13, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Ironwood Pharma and AstraZeneca began their China Phase III clinical trial of linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C). Last year, the two companies announced a $150 million pact ($25 million upfront; the remainder in sales milestones) to develop the product in China. Although the relationship was described as a joint relationship, AstraZeneca has primary administrative responsibility for China operations. More details....

Stock Symbols: (NSDQ: IRWD) (NYSE: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
ChinaBio Leadership Retreat 2014
Suzhou, China
October 23-24, 2014
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors